This page shows the latest Cancer Drugs Fund news and features for those working in and with pharma, biotech and healthcare.
Public consultation launched on Friday 6 November. The UK’s National Institute of Health and Care Excellence is finally set to review its methods of evaluation for drugs, medical devices and ... In addition, new cancer treatments can be approved via
Earlier this year, NICE initially rejected the new cancer drug, citing a lack of long-term evidence as the reason for the rejection. ... NICE said that the cost-effectiveness of the Polivy combination treatment was ‘very uncertain’, meaning it
as a treatment for kidney cancer for use within the Cancer Drugs Fund. ... number of cancer immunotherapies including Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab).
However, Revlimid will become immediately accessible with interim funding provided via the Cancer Drugs Fund, until the final guidance is published and the funding switches to routine commissioning budgets. ... Lenalidomide is a new type of targeted
The agency also says it can’t recommend the regimen for coverage by the Cancer Drugs Fund – which covers the cost of cancer drugs until confirmatory data is available – because “uncertainties ... Opdivo/Yervoy reduced the risk of death by 37% in
Ibrance. Pfizer received a positive answer from the cost-effectiveness watchdog, with NICE approving its breast cancer drug Ibrance (palbociclib) for use on the Cancer Drugs Fund. ... We are pleased that the company has agreed a managed access agreement
More from news
Approximately 53 fully matching, plus 122 partially matching documents found.
A very notable victory has just been announced, with Keytruda becoming the first of the groundbreaking immunotherapy drugs to exit the Cancer Drugs Fund and secure NICE approval for first-line ... Current projects include developing antibodies for use as
Companies have seen repeated attempts by the Government and NHS England to prevent patients from accessing new medicines, from the controversial reforms to the Cancer Drugs Fund to the ‘run rate’
In this PME market access supplement we look at the direction of travel in France and Germany and there’s an introduction to the UK’s new-look Cancer Drugs Fund.
products. In the UK, for instance, NICE now regulates access to the Cancer Drugs Fund, and products will need to meet NICE thresholds in order to be reimbursed.
Health stakeholders should focus not on the cost of drugs but on the value they provide. ... Proposed changes to the Cancer Drugs Fund in England include provision for access at a provisional price that is considered potentially cost-effective.
More from intelligence
Approximately 2 fully matching, plus 12 partially matching documents found.
Freeman's role is also tied into the Department for Business, Innovation and Skills and includes expanded responsibility for the Cancer Drugs Fund, NICE and MHRA, research and development, issues around ... the uptake of new drugs and med tech, and the
This is even more pertinent with the recent changes to the Cancer Drugs Fund, which I strongly hope will enable patients with myeloma and metastatic pancreatic cancer to continue to be
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
From the Cancer Drugs Fund to the promised Innovation Drugs Fund, initiatives have been created as technical ‘work-arounds’ for NICE and for an HTA system that has not kept pace
So, it is essential to understand the roles of local organisations, such as Primary Care Networks (PCNs) and Cancer Alliances and Rapid Diagnostic Centres (RDCs). ... of commissioning alongside the Cancer Drugs Fund and the dust has not settled yet with
topical healthcare issues including NICE, the Cancer Drugs Fund, biosimilars, the impact of Digital on pharma and the NHS in general.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....